Sunday, September 27, 2009

Endodiabology October 2009

ENDODIABOLOGY
Endodiabology.blogspot.com

NORTHEAST
NEWSLETTER
FOR SPRs AND BOSSES TRAPPED
IN THE NORTHERN DEANERY

OCTOBER 2009
Editors: Shaz Wahid and
Petros Perros and Arut Vijayaraman
Associate Editors: Shafie Kamarrudin, Ravi Erukulapati

SpR PLACEMENTS (NTN year of training from 1st October 2008)
· Newcastle- Ravi Erukalapati(5), Sudeep Manohar (3), Nimanth De Alwis (1), Arif Ullah (3), Srikanth Mada(3) Naveen Siddaramaiha (2), Sarah Steven (2)
· North Tyneside/Wansbeck- Anjali Santhakumar (3), Kathryn Stewart (3)
· South Tyneside- Rohanna Wright (2),
· Gateshead- Preeti Rao (3)
· Sunderland- Beas Bhattacharya (5) then Naveen Aggarwal (1), Chandima Idampitiya (5)
· North Tees/Hartlepool- Shafie Kamarrudin (4), Hamza Ali Khan (1)
· Middlesbrough- Freda Razvi (5), Dr Munir (1), Sajid Ethol Kalathil (1), Catherine Napier (1)
· Carlisle-
· Bishop Auckland Khaled Mansur-Dukhan (5)
· Durham- Jeevan Mettayil (4)
· NGH/QEH- Vacant
· Research with numbers (supervisor)- Eelin Lim(5-Prof Taylor); Stuart Little (2-Dr Shaw) & Asgar Madathil (4-Dr Weaver)

MEETINGS / LECTURES / ANNOUNCEMENTS
· 12th October 2009 Northern Endocrine & Diabetes Autumn CME, JCUH, Middlesbrough
· 23rd October 2009 Diabetic Foot Teaching day-for medical and surgical trainees. Freeman Hospital
· 31st October 2009 Association of Physicians, Darlington Memorial Hospital.
· 2nd-4th November 2009 Society for Endocrinology Clinical Update 2009, Manchester. Contact www.endocrinology.org
· 2nd November 2009 GIM training ½ day, Freeman Hospital. Contact Lorraine Waugh 0191 223 1247
· 3rd November 2009 RCPL Medicine Update, Freeman Hospital. Contact Lorraine Waugh 0191 223 1247
· 11th November 2009 North East Obesity Forum, 1600-1830, Newcastle University. Contact
· 19th November 2009 1st Joint Meeting of The British Thyroid Association and British Association Of Endocrine and Thyroid Surgeons, St Thomas Hospital. Contact www.british-thyroid-association.org
· 19th-20th November 2009 ABCD autumn meeting, London. Contact www.diabetologists.org.uk followed by SpRs meeting 21-22nd November 2009.
· 25th November 2009 Northern Endocrine Region Research and Audit Group annual meeting, Lumley Castle, Durham 2pm-8pm. Contact
· 26th & 27th November 2009 Middlesbrough insulin pump course. Contact
· 4th December 2009 Society for Endocrinology regional cases meeting, Edinburgh. Contact www.endocrinology.org
· 26th January 2010 Northern Endocrine & Diabetes Winter CME, Freeman Hospital. Contact
· 26th January 2010 Diabetes-A Hospital Perspective, RCPL. Contact conferences@rcp.ac.uk
· 23rd February 2010 SfE National Clinical Cases meeting, venue TBC. Contact www.endocrinology.org
· 3rd- 5th March 2010 DUK Annual Professional Conference, Liverpool. Contact www.diabetes.org.uk
· 15th – 18th March 2010 BES 2010, Manchester. Contact www.endocrinology.org.
· 28th April 2010 RCP Acute Medicine symposium, Freeman Hospital. Contact Lorraine Waugh 0191 223 1247 Lorraine.waugh@tfh.nuth.northy.nhs.uk.
· 6th-7th May 2010 ABCD Spring Meeting, The Hilton, GATESHEAD. Contact www.diabetologists.org.uk
· 8th June 2010 Northern Endocrine & Diabetes Spring CME, Freeman Hospital. Contact mshafie_kamaruddin@yahoo.co.uk
· 19th – 22nd June 2010 ENDO 2010, San Diego, USA. Contact endostaff@endo-societ.org or www.endo-society.org/scimeetings .
· 25th – 29th June 2010 American Diabetes Association 70th Annual Scientific Sessions, Orlando, Florida, USA. Contact meetings@diabetes.org .


TRAINING ISSUES
DIABETES & ENDOCRINOLOGY PIMD WEBSITE Our specialty website is available on http://mypimd.ncl.ac.uk/PIMDDev . Click onto the specialty training tab then follow to Diabetes & Endocrinology. This site is essential reading, especially for ARCP preparation.
A new Trainee Rep With Arut now having his CCT AND Consultant post an opportunity for a new trainee rep has arisen on the STC. SEE OUR TPDs REGULAR LETTER BELOW.
A novel training opportunity Any one interested in working towards a diploma or MSc in Public Health? If yes, SEE OUR TPDs REGULAR LETTER BELOW.
More Consultant members If you would like to be involved with the STC please do contact Nicky Leech ASAP.
ARCP (RITA) The next round is due on Weds 12th, Thurs 13th & Fri 15th May 2010. Trainees please keep these dates free as possible.
Registering with PMETB It is essential that all new SpRs/StRs (even LATs) register with the PMETB through the newly created Joint Royal Colleges of Physicians Training Board (formally the JCHMT) on www.jrcptb.org.uk. Not doing so means your training is not counted.
Log Book/Portfolio Documentation It is a trainee’s responsibility to make sure their portfolio/log book is prospectively completed and the necessary signatures obtained. Any experience that is not signed off by your educational supervisor at the time cannot be counted towards training. The e-portfolio for DM&ENDO is available now for StRs.
Assessment tools Please see www.jrcptb.org.uk; it is the trainee’s responsibility to give all the appropriate forms to their Educational or Clinical Supervisor. It is the trainee’s responsibility to make sure that the appropriate assessment summaries are available in their portfolio for ARCP purposes, e.g. MSF Summary Form.
Acute Care Assessment Tool The ACAT is a tool that is commendable. It provides a method of assessing how Trainees managed their on-call period. It is recommended that at least one is available for ARCP purposes. It can be downloaded from the JRCPTB website.
Case Based Discussions (CbD) The pilot form is available from the JRCPTB website. It is a must for trainers to use as a tool to document feedback in clinic. This has always been done informally, but now there is a method to formally document it. It can be used for when a SpR presents a new case in clinic.
Documenting CCU and ITU experience It is essential that trainees document their CCU and ITU experience. This is best done by keeping a summary log of the cases seen on CCU and ITU and linking it with reflection or assessment. This should then be signed off by your Educational Supervisor to be of any use at the Acute Medicine PYAs.
Audit Assessment tool This is now available in draft form on the JRCPTB website. Its use is highly recommended.
General Internal Medicine Curriculum is now updated and available on www.jrcptb.org.uk. All trainees appointed ST3 from August 2009 will be offered entry to train for this CCT. Trainees before this date can easily apply to train in this CCT (i.e. dual accredit), again detailed in the website. Reviewing the new curriculum for G(I)M each trainee will need 6 ACATs, 4-CBDs and 4 Mini-CEXs in G(I)M as well as the specialty work based assessments. The publication of this curriculum and the formation of a National SAC in G(I)M separate from the Acute Medicine SAC really does mean that in practical terms the 2 specialties will be split entirely in 5-10 yrs. Our current G(I)M/Acute Medicine STC is preparing for this split, but will continue to have a dual function up to the point when there are enough Acute Medicine trained Physicians in the region to allow the formation of 2 different STCs. What this space.......................................................................................
MRCP Diabetes & Endocrinology This exam has to be completed and passed by all trainees appointed after August 2007 before their PYA. We recommend sitting it ASAP and well before your PYA.
Personal Development Plans Each trainee should use their ARCP/RITA report to construct a PDP and discuss with their Educational Supervisor. A copy of the PDP should be sent to Nicky Leech by 26th Nov 2009.
INFORMATION for QA Could each individual trainer send the following to Simon Pearce: educational qualifications, any training positions held and any educational courses attended.
MORE INFORMATION for QA Could each unit’s Training Lead please send to Simon Pearce a completed training unit information report and an updated SpR/StR job description as per Nicky Leech’s e-mail.
Trainers & Trainees meeting The next T&T is on 24th June 2010. Details to be confirmed nearer the time, but please note in your diary.
Training Committee Chair- Simon Pearce,; Regional Speciality Advisor- Shaz Wahid; Programme Director- Nicky Leech Consultant member (SAC rep)- Richard Quinton, Consultant member-Jean MacLeod,; Consultant member-Vacant; Consultant member-Simon Eaton,; SpR representative- Vacant; SpR representative- Jeevan Mettayil

NEWS FROM THE NORTHEAST
· Congratulations to Arut on appointment to a Consultant post at James Cook University Hospital in Diabetes&Endo. He already has his feet under the table.
· Congratulations to Jeevan Mettayil on being appointed the Regional Rep for the Young Diabetologists Forum.
· Congratulations to Ravi on his PhD “Postprandial metabolism in health and type 2 diabetes”.
· ABCD is coming to town. Please note that this excellent national meeting will be visiting the region on 6-7th May 2010 at the Hilton in Gateshead. See above.
· Simon Pearce is the new Chair of the STC.
· Keep an eye out for the annual RCP Acute Medicine Symposium on 28th April 2010 at FRH. Yours truly will be presenting with the title “Sugar and Hormones in the Acute Unit”.
· There are a number of new trainees on the scene, welcome to you all: Catherine Napier, Hamza Ali Khan, Naveen Aggarwal, Munir, Sajid Ethol Kalathil, Nimanth De Alwis. Please excuse, any spelling errors. The “drums” are not quite that accurate just yet.
· Congratulation s to Rohana Wright on her recent marriage.

LETTERS

The 8th Habit-From Effectiveness to Greatness-Shaz Wahid
I did warn you I would be writing about this and this is not at all about becoming a megalomaniac! This excellent book by Stephen Covey is a must read once you have read about the 7 habits of effectiveness and more importantly after practicing them for at least 1 year. It is all about finding your own voice and then helping others to find their voice. I have found the principles of the 8th habit very useful in my professional activities of late. I have been involved in a major change project within the Trust. As ever such a project has resulted in much angst, frustration and confrontation. I clearly found my voice in relation to this major project a long time ago and based it on sound principles of quality patient care, safe patient care, cost-effective patient care and quality training all rolled into a MISSION STATEMENT in the form of a VISSION. My organization is aligned towards this vision and the task of getting others aligned towards this vision has begun with everyone accepting the VISSION. The challenge is keeping everyone aligned towards the vision along the curvy path. This is best done by helping others to find their voice in relation to the vision and helping the alignment towards it. I have deliberately kept this description general. Those of you who know me have probably worked out this is about my activities around shaping emergency care at South Tyneside. However, I am also using the same principles in reshaping Diabetes care in the District in negotiations with the commissioners. Once you have got to grips with the 7-habits the 8th habit is a must do.


The dark side-Shaz Wahid
I think I shocked Petros when I met him at the RITAs and let it slip I will be going towards management! I have grown up with a healthy dollop of mistrust when it comes to the management. So what has changed my mind. Well it has all got to do with instituting change. Knowing the workings within my Trust has helped me institute change, although some would say or get what I want or Empire Build. But, to truly effect change and help others in contributing to change I need to be a in a position of influence. So the first steps have started with:
-getting onto the Executive Board as Clinical Lead for the Emergency Care Pathway
-getting onto and actively participating in governance groups such as the Clinical Incident Review Group and Mortality Review Group
-plans to attend a conference titled “Effective Clinical Director”, covering areas such as revalidation, measuring & monitoring clinical outcomes and PROMs, lean thinking, quality metrics and managing poor performance & dealing with difficult Drs
-Subscribing to the Health Service Journal
-Joining the British Association of Medical Managers (BAMM)
They are all first steps and I guess watch this space……………….. Although, it is important to have an escape route otherwise the trap door looms large. This route is the full retirement of an Everton supporter in 2011! For more information visit bamm.co.uk and for you yunguns, here is a plug for BAMMbino:

In recent years, it has become increasingly apparent that the medical profession needs to develop high quality leadership and management skills in order to effectively participate in the great healthcare debate. Work by the Royal Colleges, NHS Institute for Innovation and Improvement and BAMM has called for these skills to be nurtured from an early stage in doctor's careers, but there is little support and advice for those who wish to be the Clinical Directors, Medical Directors and Chief Medical Officers of the future.
At BAMMbino, we intend to create a living network of enthusiastic Junior Doctors who see medical management and leadership as an intrinsic part of their future careers. By acting as a portal for information, advice and support we will be building on the ethos of BAMM to help create a new generation of doctors who will be able to work proactively in and with the ever-changing healthcare environment.
Our intention is to deliver a service that will guide our members through the latest hot topics, encourage their own attempts to improve services for patients, and help mentor them through the ups and downs of their individual careers.
If you are a keen medical student, F1, F2, SHO or SpR who shows an interest in the ‘bigger picture' then let us know by sending their details to BAMMbino@bamm.co.uk This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
' );
//-->

and we will try to make their journey a little smoother than those who have gone before.
GOSSIP FROM THE TPD-Nicky Leech
Congratulations to Arut Arutchelvum on his appointment as a consultant at James Cook University Hospital. This leaves a vacancy for an SPR on the Specialist training committee. This is a position of great responsibility representing the views and needs of Diabetes & Endocrinology trainees across the NE, working with consultant members of the committee to continue to develop training in the NE Deanery. Application is by e-mail . You need to submit a 300 word maximum answer on the question ---

What recommendation would you make to the STC regarding developing the training programme to better prepare trainees for Consultanthood?

Application should be sent by e-mail to me on .. Nicola.leech@nuth.nhs.uk

Closing date: October 30th 2009. The entries will be judged and scored by the STC and the results announced at NEERAG on 18th November 2009.
Also…
I am interested in hearing from any trainees interested in training in and working towards a diploma or MSc in public Health. We have an opportunity to secure funding and supervision through “Darzi” Money for part-time training in public Health. It may be possible to combine this with clinical diabetes but the details of the job may be customised around the wishes and needs of the applicant . Therefore anyone interested at this stage should contact me personally and I will discuss it further with them.

Summer Camp for Kids with Diabetes at Marrick Priory-A Santhakumar
Attending the paediatric diabetes outpatient clinics at James Cook University hospital I got the wonderful opportunity to be a part of their annual kids camp at Marrick Priory and wish to share my experience. Set in the scenic Yorkshire Dales , the Marrick Priory has been hosting this immensely popular children’s camp for years. The enthusiasm of the children and their parents at the diabetes outpatient clinics led me to sign up as part observer/counsellor at this year’s activities camp for children with diabetes. The summer camp had 30-35 kids aged between 9-13 years and for some of them it was the first time away from their parents. The camp staff and counsellors included the camp warden, senior and junior medical officers, diabetes nurses, dieticians, psychologists and junior leaders who had diabetes themselves.

I arrived at the camp early Friday morning to find children being lined up into 4 groups. My group had 8 children and as counsellors the group had a senior paediatrician, a paediatric registrar, an adult diabetes registrar (yours truly) and a dietician. At the camp the staff to kids ratio was maintained at around 1:2 and there was close supervision during all sports and outings. To ensure safety and optimal diabetes management, multiple blood glucose determinations were made throughout each 24-h period
Attempts were made to follow the home insulin regimen of each camper as closely as possible. However, most camps have found it advisable to decrease the home insulin dosage by 10–20% (or more) on arrival at camp, especially in those children under good control who were not active before the camp session.
The day was jam packed with activities like kayaking, archery, rock climbing and obstacle courses to name just a few. The enthusiasm and the excitement of the kids were infectious and we had to remind ourselves that all these kids had type 1 diabetes and could potentially have a hypoglycaemic episode atop a tree or in a kayak!

Meal times provided an excellent opportunity to educate and encourage children about insulin adjustments and carbohydrate counting. Many of the kids gave their first independent insulin shots at the camp. The camp also provided these youngsters an opportunity to help out younger campers and learn to be responsible. Using the active camping environment as a teaching opportunity was an extremely useful way for children with diabetes to gain skills in managing their disease within the supportive camp community. It was all about having a positive experience learning how to manage their diabetes. In fact most of the kids who attend these camps frequently return and often volunteer as counsellors themselves which is indicative of how much they value their time spent in these camps.

On the whole (apart from a terrifying personal moment during a free fall exercise!) it was a thoroughly enjoyable and an extremely enriching experience for me. It gave me a whole new perspective on management of diabetes in the young and I would recommend my fellow registrars to try and attend a similar camp at least once .

What these camps offer the kids
· Diabetes camp is one of the best experiences that a child with diabetes can have. It is a place where the norm is to have diabetes and they no longer feel ‘different’.
· A fun and safe camping experience. Many will meet new friends with whom they will keep in touch for years to come.
· An emphasis on achieving good control of diabetes while adjusting to daily activities.
· Opportunity to develop self confidence and independently manage their diabetes.
· Diabetes education in an informal setting.
· It is an opportunity to gain independence from mom and dad, to be with other kids with diabetes, and simply to have a great time.
· It's also an excellent opportunity for mom and dad to take a break from diabetes!
What the camps can offer us
· Fun practical experience in insulin management during exercise.
· Insight and a whole new perspective into what it means to live with diabetes.
· Opportunity to educate in an informal environment far removed from the clinic setting and to be creative when imparting skills and knowledge!
· Understand the pathos that comes from being responsible for a young person with diabetes.
· Amazing eye opener in how quickly kids grasp new knowledge, accept change and just get on with it!
· Useful tips to incorporate informal teaching techniques in the management of young people in the adult diabetes service.
Diabetes UK has been organizing holidays for children since 1930s with about 500 kids participating each year. Details about similar camps in our region is available on their website. http://www.diabetes.org.uk/Professionals/Resources-for-patients/Care-events/
The Firbush Project, run by Perth Royal Infirmary provides a similar annual adventure camp for 16-21 year olds on Loch Tay. Details are available on NHS Tayside website http://www.diabetes-healthnet.ac.uk/HandBook/DiabetesAndTeenagers.aspx


RECENT PUBLICATIONS FROM THE NORTHEAST
1. Kamaruddin MS, Quinton R, Leech N. 2009 Inpatient diabetes care: first do no harm? Clinical Services Journal. 6: 37-40.
2. Arun CS, Al-Bermani A, Stannard KS, Taylor R. Long term impact of retinal screening upon significant diabetes related visual impairment in the working age population. Diabetic Medicine 26:489-492, 2009.
3. Jovanovic A, Leverton E, Solanky B, Snaar JEM, Morris PEG, Taylor R. The second meal phenomenon is associated with enhanced muscle glycogen storage. Clin Sci 117:119–127, 2009.
4. Al-Ozairi E, Waugh JJS, Taylor R. Termination is not the treatment of choice for severe hyperemesis gravidarum: Successful management using prednisolone. Obstetric Medicine 2: 34-37, 2009.
5. Lim EL, Burden T, Marshall SM, Davison JM, Blott MJ, Waugh JJS, Taylor R. Intrauterine Growth Rates in Pregnancies Complicated by Type 1, Type 2 and Gestational Diabetes. Obstetric Medicine 2: 21-25, 2009.
6. Jovanovic A, Gerrard J, Taylor R. The second meal phenomenon in type 2 diabetes. Diabetes Care 32:1199-1201, 2009.
7. L. Sibal, A. Aldibbiat, S. C. Agarwal, G. Mitchell, C. Oates, S. Razvi, J. U. Weaver, J. A. Shaw and P. D. Home. Circulating endothelial progenitor cells, endothelial function, carotid intima–media thickness and circulating markers of endothelial dysfunction in people with type 1 diabetes without macrovascular disease or microalbuminuria. Editors choice August 09 Diabetologia www.diabetologia-journal.org
8. Wright R J, Frier B M, Deary I J. Effects of acute insulin-induced hypoglycemia on spatial abilities in adults with type 1 diabetes. Diabetes Care 2009; 32: 1503-1506.

RECENT PUBLICATIONS IN DIABETES & ENDOCRINOLOGY THAT HIT THE NEWS OR THAT MAY HAVE A SIGNIFICANT IMPACT ON MANAGEMENT

Denosumab in men receiving androgen-deprivation therapy for prostate cancer. Smith MR, Egerdie B, Hernández Toriz N et al N Engl J Med. 2009 Aug 20;361(8):745-55. Androgen-deprivation therapy is well-established for treating The authors investigated the effects of denosumab, a fully human monoclonal antibody against receptor activator of nuclear factor-kappaB ligand (RANKL) that blocks its effect on the RANK receptor reducing osteoclast activity and hence bone resorption with an intendent increase in bone mineral density, on bone mineral density and fractures in men receiving androgen-deprivation therapy (which increases fracture risk) for nonmetastatic prostate cancer. 734 patients were randomized to receive denosumab 60 mg subcutaneously every 6 months and 734 patients received placebo . The primary end point was percent change in bone mineral density at the lumbar spine at 24 months and secondary end points included percent change in bone mineral densities at the femoral neck and total hip at 24 months and at all three sites at 36 months, as well as incidence of new vertebral fractures. At 24 months, lumbar spine BMD increased by 5.6% in the denosumab group as compared with a loss of 1.0% in the placebo group (P<0.001); Denosumab therapy was also associated with significant increases in BMD at the total hip, femoral neck, and distal third of the radius at all time points. Denosumab reduced the incidence of new vertebral fractures at 36 months by 62% (1.5%, vs. 3.9% with placebo; relative risk, 0.38; 95%CI 0.19 to 0.78; p=0.006). Rates of adverse events were similar between the two groups. In this trial Denosumab was associated with increased bone mineral density at all sites and a reduction in the incidence of new vertebral fractures.

Denosumab for prevention of fractures in postmenopausal women with osteoporosis. Cummings SR, San Martin J, McClung MR N Engl J Med. 2009 Aug 20;361(8):756-65. The investigators enrolled 7868 women between the ages of 60 and 90 years with a BMD T score of < -2.5 but not <-4.0 at the lumbar spine or total hip and randomly assigned them to receive either 60 mg of denosumab or placebo subcutaneously every 6 months for 36 months. The primary end point was new vertebral fracture with secondary end points of nonvertebral and hip fractures. Compared to placebo denosumab reduced the risk of new radiographic vertebral fracture by 68% (cumulative incidence of 2.3% vs 7.2%; risk ratio, 0.32: 95%CI 0.26-0.41; p<0.001). Denosumab reduced the risk of hip fracture by 40% (cumulative incidence of 0.7% vs 1.2%; hazard ratio, 0.60: 95% CI, 0.37-0.97; p=0.04). Denosumab also reduced the risk of nonvertebral fracture by 20% (cumulative incidence of 6.5% vs 8.0%; hazard ratio, 0.80: 95% CI, 0.67-0.95; p=0.01). There was no increase in the risk of cancer, infection, cardiovascular disease, delayed fracture healing, or hypocalcaemia, and there were no cases of osteonecrosis of the jaw and no adverse reactions to the injection of denosumab. The above two trials clearly demonstrate the effectiveness of targeting RANKL to treat osteoporoses in both men and women. Denosumab is an exciting new tool for treating osteoporoses. The accompanying editorial by Sundeep Khosla (NEJM 2009;361:818-820) is well worth a read. The challenge now is construct cost effective pathways for utilising the therapies available for osteoporoses.

Recent developments in hyperthyroidism. Julia Kharlip and David S Cooper. Lancet 2009;373:1930-1932. A reasonable editorial that will point you to the true goodies to read.

Eradication of insulin resistance. Imai J, et al. Lancet 2009;374:264. An excellent case report.

Hyperparathyroidism. William D Fraser. Lancet 2009;374:145-158. An excellent review well worth a read.

A reason to panic in pregnancy. Pearson GAH et al. Lancet 2009;374:756. An excellent case report exploring catecholamine excess in pregnancy.

Insulin glargine and malignancy: an unwarranted alarm. Stuart J Pocock & Liam Smeeth. Lancet 2009;374:511-513. AND Insulin glargine and cancer: another side to the story? Edwin AM Gale. Lancet 2009;374:521. An editorial and correspondence that I think provide food for thought, pause and appraisal............

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Home PD, Pocock SJ, Beck-Nielsen H, et al Lancet. 2009;373:2125-35. The investigators randomized 4447 patients with type 2 diabetes on metformin or sulfonylurea monotherapy with mean HbA1c of 7.9% to the addition of rosiglitazone (n=2220) or to a combination of metformin and sulfonylurea (active control group, n=2227). The primary endpoint was cardiovascular hospitalisation or cardiovascular death. The latter occurred in 321 people in the rosiglitazone group and 323 in the active control group during a mean follow-up of 5.5 years. The Hazard Ratio[95%CI] was 0.84[0.59-1.18]for cardiovascular death, 1.14[0.80-1.63] for MI, and 0.72[0.49-1.06] for stroke. Hospital admission for heart failure or death occurred in 61 people in the rosiglitazone group and 29 in the active control group (HR 2.10[1.35-3.27]) Upper (Risk Ratio[95%CI] 1.57[1.12-2.19], p=0.0095)and distal lower limb (2.6[1.67-4.02], p<0.0001) fracture rates were increased mainly in women assigned to rosiglitazone. Mean HbA1c was lower in the rosiglitazone group than in the control group at 5 years, mean[SE] HbA1c rosiglitazone vs sulfonylurea -0.28[0.03] vs 0.01[0.04], p<0.0001; rosiglitazone vs metformin -0.44[0.03] vs -0.18[0.04], p<0.0001. This trial really does confirm my working practice that glitazones are effective therapy for improving glycaemic control in patients with Type 2 DM, but they should not be used in patients with heart failure or at significant risk of heart failure; the fracture risk of all patients should be assessed before starting therapy AND that they do not increase overall cardiovascular mortality or morbidity. Their use really is guided by discussion with the patient. The generic advice in guidelines or to GPs of a glitazone of your choice remains for me.

The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. van Hylckama Vlieg A, Helmerhorst FM, et al BMJ. 2009 Aug 13;339:b2921. doi: 10.1136/bmj.b2921. This population based case-control study assessed the thrombotic risk associated with oral contraceptive use with a focus on dose of oestrogen and type of progestogen of oral contraceptives in premenopausal women <50 years old who were not pregnant, not within four weeks postpartum, and not using a hormone excreting intrauterine device or depot contraceptive, with a population of 1524 patients and 1760 controls. Currently available oral contraceptives increased the risk of venous thrombosis fivefold compared with non-use (odds ratio 5.0, 95%CI 4.2 to 5.8). The risk clearly differed by type of progestogen and dose of oestrogen. The use of oral contraceptives containing levonorgestrel was associated with an almost fourfold increased risk of venous thrombosis (odds ratio 3.6, 2.9 to 4.6)compared to non-users, whereas the risk of venous thrombosis compared with non-use was increased 5.6-fold for gestodene (5.6, 3.7 to 8.4), 7.3-fold for desogestrel (7.3, 5.3 to 10.0), 6.8-fold for cyproterone acetate (6.8, 4.7 to 10.0), and 6.3-fold for drospirenone (6.3, 2.9 to 13.7). The risk of venous thrombosis was positively associated with oestrogen dose. There was a high risk of venous thrombosis during the first months of oral contraceptive use irrespective of the type of oral contraceptives. Reviewing the results of this study and another study (Hormonal contraception and risk of venous thromboembolism: national follow-up study. Lidegaard O, et al. BMJ 2009;339:b2890doi10.1136/bmj.b2890) along with an excellent review (Contraception for women: an evidence based overview. Jean-Jacques Amy & Vrijesh Tripathi. BMJ 2009;339:b2895 doi10.1136/bmj.b2895) in the same issue of the BMJ show that when discussing oral contraception with women we should recommend those containing levonorgestrel or norethisterone with as low a dose of oestrogen as possible. The accompanying editorial by Nick Dunn (BMJ 2009;339:b3164doi:10.1136/bmj.b3164) is well worth a read.






NEXT NEWSLETTER Due out beginning of February 2009 so keep the gossip coming.

Sunday, October 14, 2007

ENDODIABOLOGY
Endodiabology.blogspot.com

NORTHEAST
NEWSLETTER
FOR SPRs AND BOSSES TRAPPED
IN THE NORTHERN DEANERY

OCTOBER 2007
Editors : Shaz Wahid and Petros Perros
Associate Editors : Freda Razvi, Akheel Syed, Arutchelvam Vijayaraman

SpR PLACEMENTS (NTN year of training from 1st October 2007)
· RVI- Andrew Advani (5), Arutchelvan Vijayaraman (4), Jeevan Mettayil (3), Muthu Jayapaul(5), Khaled Mansur-Dukhan (4)
· Freeman- Chandima Idampitiya (3), Ravikumar Balasubramanian (5), Kerry Livingstone (2)
· North Tyneside/Wansbeck- Akheel Syed(5), Sukesh Chandran(4)
· South Tyneside- Kathryn Stewart (1)
· Gateshead- Asgar Madathil (4)
· Sunderland- Shafie Kamarrudin (2), LAT
· North Tees/Hartlepool- Beas Bhatacharya (4), Anjali Santhakumar (1)
· Middlesbrough- Srikanth Mada(1), Ravi Erukalapati(3), Preeti Rao
· Carlisle- Sudeep Manohar
· Bishop Auckland / Durham- Sony Anthony (5), Arif Ullah (1)
· NGH/QEH- Freda Razvi (3)
· Research with numbers (supervisor)- Eelin Lim(4-Prof Taylor)

MEETINGS / LECTURES / ANNOUNCEMENTS
· 8th October 2007 Northern Endocrine & Diabetes Autumn CME, James Cook University Hospital. Contact Arutchelvam Vijayaraman
· 16th October 2007 Regional Diabetes Audit Group meeting, preceded by NRDSAG. Contacts K Narayanan and Simon Eaton
· 19th October 2007 Deadline for submission of abstracts to DUK for APC in March 2008.
· 31st October 2007 National Training Scheme for the use of radioiodine in benign thyroid disease, Birmingham. Contact Helen Flood
· 1st November 2007 57th British Thyroid Association Annual meeting, London
· 1st-2nd November 2007 (3rd November is SpR meeting) ABCD Autumn Meeting, London, http://www.diabetologists.org.uk/
· 3rd November 2007 Association of Physicians meeting, Freeman Hospital. Contact clive Kelly at Queen Elizabeth hospital, Gateshead
· 5th-7th November 2007 Society for Endocrinology Clinical Update 2007, Manchester. Contact http://www.endocrinology.org/
· 15th November 2007 Deadline for submission of abstracts to Society for Endocrinology for BES conference in April 2008
· 21st November 2007 GIM training ½ day, Freeman Hospital. Contact Lorraine Waugh 0191 223 1247 Lorraine waugh
· 28th November 2007 Northern Endocrine Region Research and Audit Group annual meeting, Lumley Castle, Durham 2pm-8pm. Contact Shaz Wahid
· 3rd December 2007 UK Neuroendocrine Tumour Society Conference, London. Contact Rebecca Hannah uknets@banks-sadler.co.uk
· 4th December 2007 RCP Update in Medicine, Freeman Hospital. Contact Lorraine Waugh 0191 223 1247 Lorraine waugh
· 14th January 2008 GIM training ½ day, Freeman Hospital. Contact Lorraine Waugh 0191 223 1247 Lorraine waugh
· 29th January 2008 Northern Endocrine & Diabetes Winter CME, Freeman Hospital. Contact Arutchelvam Vijayaraman
· 26th February 2008 Clinical Cases Meeting, Society for Endocrinology, London. Contact http://www.endocrinology.org/
· 5th-7th March 2008 DUK Annual Professional Conference, Birmingham. Contact http://www.diabetes.org.uk/
· 17th March 2008 GIM training ½ day, Freeman Hospital. Contact Lorraine Waugh 0191 223 1247 Lorraine waugh
· 7th-10th April 2008 BES 2008, Harrogate. Contact http://www.endocrinology.org/
· 10th-11th April 2008 ABCD Spring Meeting (follows straight after BES), Harrogate, http://www.diabetologists.org.uk/
· 16th April 2008 RCP Acute Medical Emergencies conference, Freeman Hospital. Contact Lorraine Waugh 0191 223 1247 Lorraine waugh
· 6th May 2008 Northern Endocrine & Diabetes Summer CME, Freeman Hospital. Contact Arutchelvam Vijayaraman
· 8th October 2008 Northern Endocrine & Diabetes Autumn CME, James Cook University Hospital. Contact Arutchelvam Vijayaraman
· Endocrinology & Diabetes section of the RSM (www.rsm.ac.uk/endocrinology) offers the following meetings beginning at 9am: Thursday 1 Nov 07: Diabetes for Hospital Doctors. Wednesday 23 Jan 08: Adolescent Endocrinology (joint with Paed/Child Health) Wednesday 27 Feb 08: Diabetes in the Elderly (joint with ABCD) Wednesday 28 May 08: Evidence-based Endocrinology

TRAINING ISSUES
DIABETES & ENDOCRINOLOGY PIMD WEBSITE Our specialty website has been redesigned and is now available on http://mypimd.ncl.ac.uk/PIMDDev . Click onto the specialty training tab then follow to Diabetes & Endocrinology. This site is essential reading, especially for RITA preparation.
Registering with PMETB It is essential that all new SpRs/StRs (even LATs) register with the PMETB through the newly created Joint Royal Colleges of Physicians Training Board (formally the JCHMT) on http://www.jrcptb.org.uk/ although it is still possible to link with this site using the old http://www.jchmt.org.uk/ link. Not doing so means your training is not counted.
Log Book/Portfolio Documentation It is a trainee’s responsibility to make sure their portfolio/log book is prospectively completed and the necessary signatures obtained. Any experience that is not signed off by your educational supervisor at the time cannot be counted towards training.
Assessment tools Please see http://www.jrcptb.org.uk/, It is the trainee’s responsibility to give all the appropriate forms to their Educational or Clinical Supervisor. It is the trainee’s responsibility to make sure that the appropriate assessment summaries are available in their portfolio for RITA purposes, e.g. MSF Summary Form.
Laboratory Training Following SpR feedback, the STC has prepared a document providing guidance for training units and SpRs on the minimum training to be provided in relation to this important subject. It can be accessed on http://mypimd.ncl.ac.uk/PIMDDev .
ANOTHER CURRICULUM!!! Trainees who have been recently appointed now have a new curriculum for both the specialty, Acute Medicine to Level 2 and a generic curriculum. Essentially there is no difference other than the sections being reorganised into the subsections of OBJECTIVE/COMPETENCY, KNOWLEDGE, SKILLS, ATTITUDE. They are essential reading and can be accessed on http://www.jrcptb.org.uk/ .
The GOLD Guide This replaces the Orange guide, and is the definitive guide to all aspects of training in the UK. It can be accessed on http://www.jrcptb.org.uk/SiteCollectionDocuments/Gold%20Guide.pdf . A massive document that I delve into when the need arises, e.g. interdeanery transfers.
REPLACING RITA MMC/PMETB/JRCPTB has produced new guidance on assessing trainees’ progression. The RITA will be replaced with the Annual Review of Competence Progression. ARCP for short. Our region already fulfils the majority of the guidance as the RITAs were revamped 2-yrs ago. Further guidance will be issued in early 2008, once the TPD has been on the course!
ARCP (RITAs 2008) Next year they will be held on Weds 14th, Thursday 15th and Friday 16th May 2008. The PYAS are planned for Thursday am 15th May 2008. An early timetable has been circulated with initial guidance to trainees. Please reply to Shaz Wahid ASAP.
PERSONAL DEVELOPMENT PLANS One of the recommendations of the new Gold Guide is for each trainee to document a PDP at the beginning of each new post. This is something the STC will provide future guidance on, but it would do no harm for trainees to develop one at the start of their current training unit. A suggested template: What development needs have I? How will I address them? Date by which I plan to achieve development goal? Outcome? Completed? Another suggested template: What do I need to learn? How am I going to learn this? What resources do I need to achieve the learning? How will I measure when I have achieved this? How long will this take?


Training Committee Chair- Jola Weaver, Regional Speciality Advisor- Richard Quinton, Programme Director- Shaz Wahid,consultant member-Jean McLeod,consultant member (Research Advisor)-Simon Pearce, Consultant member-Simon Eaton, Consultant member-Nicky Leech SpR representative- Arutchelvan Vijayaraman SpR representative-Andrew Advani
NEW FACES ON THE SCENE
· Welcome to Kathryn Stewart, Anjali Santhakumar, Arif Ullah and Sudeep Manohar as new SpRs (now called StRs (Specialty Trainees) to the region.
· Welcome to Chris Strey as Consultant Endocrinologist at Wansbeck. Since graduation from medical school in Munich, Germany, Chris has been practicing medicine in England for eleven years; interrupted by a three year - PhD programme in New Zealand. He has been working in diabetes and endocrinology for the last eight years completing his specialty training at Addenbrooke’s Hospital, Cambridge University. His research interests focus on endothelial dysfunction in health and disease and endothelial hormones.

NEWS FROM THE NORTHEAST
· It may be a little early to officially announce, but unofficially then!, congratulations to Professor Simon Pearce on his Chair.
· Congratulations to Peter Carey on obtaining the Consultant post at Sunderland Royal. Also, our congratulations to Pete and family on the birth of his daughter Maebh which occurred just after the last newsletter was published.
· Congratulations to Salman Razvi on obtaining the Consultant post at Gateshead.
· Congratulations to Sony Anthony on obtaining the Consultant post at Hartlepool, he plans to act up before his CCT date.
· Reena Thomas will be undertaking a Locum Consultant post at Rochdale from October 2007.
· Congratulations to Srikanth Mada on obtaining his NTN at the recent interviews.
· Nicky Leech has joined the STC as a Consultant member.
· Our best wishes to Ebaa Al-Ozairi as she returns to Kuwait.
· Freda Razvi has returned from her period of career break in a part-time capacity.
· Richard Quinton has joined the Specialist Advisory Committee for Diabetes & Endocrinology, representing the Northern Deanery.
· Kerry Livingstone has joined the NED CME committee with Arut.
· Congratulations to Arut on his recent oral presentation at EASD titled “changes in plasma glucose following exercice:comparison of three basal insulins, V. Arutchelvam , T. Heise, S. Dellweg, B. Elbroend, I. Minns, P. D. Home”.
· Congratulations to Simon Eaton on being selected as Lead Clinician for Care Planning in Diabetes leading the national engagement and implementation of Care Planning with the National Diabetes Support Team and the Department of Health.

LETTERS
Contributions for this section can include meeting reports, research experiences, book reviews, experiences abroad, and anything else you feel may benefit trainees and trainers around the region. The success of this section really does depend on YOU.

Is Management for me?-Shaz Wahid
Having been a Consultant for 4-years I am now asked whether I would like to develop “formal” management skills by a number of individuals at the Trust and attend some regional/national events. Basically, it is a “code” for do you want to join “The Management”? There are 2 courses I could attend, the Kings Fund Development Programme for Diabetologists or the regional NHS course supported by the StHA and the PIMD (I was nominated by Nancy Redfern and my MD). Having looked at the course objectives both of them have a number of objectives which I have already obtained. This is backed up in my portfolio with reflection and via the BMJ Learning website with completed modules and practical examples from my working practice. My activities over the last 4-yrs in relation to Programme Director, Specialty service redesign and more recently Leading the clinical input into redesigning Acute Medicine at the Trust have required obvious managerial skills. If it had not been for this activity I certainly would have booked up on either of the latter courses for my own professional development. However, I personally at this point in time can not see myself wishing to reduce my clinical activities in the future to take on a formal management role. I still enjoy the “coal” face both when delivering a clinical service or an educational “service”. Joining “Management” at the moment is not right for me. My advice to those Consultants recently appointed is that trying to get onto a formal management course (the Kings Fund Course is probably the best one) would be worthwhile for professional development and is certainly a stepping stone to joining “The Management” in the future.

Laboratory Training-Shaz Wahid
As specialists we are frequently asked to comment on investigation that seems out of the “box”, e.g. funny TFTs. Having a working knowledge as to what the Labs do” is therefore essential and helps in test interpretation. It is part of being a specialist! Following SpR feedback the STC have produced the following guidance:
It is important to arrange exposure to laboratory medicine during each unit attachment backed up by background reading. It is important to cover the following topics:
n HbA1c assay measurement, cv, standardisation
n Glucose measurements in the lab and meters with causes of errors
n Hormone assay methods
n Immunometric; RIA, ELISA
n Chromatography
n Reasons for variability+errors, eg hook effect, protein binding
n Pitfalls in autoAb measuring, e.g. TBII, thyroid, adrenal
n Pitfalls in measuring or assessing the following hormones or endocrine axis
n TSH, fT4, fT4, thyroglobulin, total thyroid hormones
n Prolactin
n Cortisol, ACTH
n PTH, calcitonin, calcium, vitamin D
n Water & electrolyte handling; electrolytes, osmolality, ADH
n GH, IGF1
n LH, FSH, Testosterone, SHBG, E2
n Renin, aldosterone, PRA
n Catecholamines

The domains of a Consultant Diabetologist/Endocrinologist-Shaz Wahid
“A review of job satisfaction and current practice of consultant diabetologists in England-barriers and successes, MacLeod K, et al. Diabetic Medicine September 2007;24:946-954” is essential reading for ALL, including Endocrinologists! It is a wonderful collection of thoughts on what a Consultant in Diabetes&Endocrinology truly is in practice. There are 3 basic domains to being a specialist in our specialty:
Clinical Specialist Skills
Leadership Skills across boundaries
Clinical Educator














Each of the domains overlap and pertain to clinical activity, management activity, research activity, governance activity, etc. It is essential for trainees to develop these domains during their training. We far too often concentrate on the clinical skills development that is guided by the curriculum, but it is important to bear in mind that there is ample opportunity for the development of subspecialty skills (diabetic foot, transitional care, etc). It is important to develop leadership skills (eminently demonstrated by Simon Eaton in the letter below) and to undertake activity during training demonstrating these skills, e.g. rota leader, audit resulting in service change that is implemented by the trainee. It is important to demonstrate effective activity as a clinical educator of patients, students, junior Drs, allied health professionals, peers in the hospital and community. When undertaking PYAs one can get a sense of which domains have been developed by the trainee. I highly recommend reading this important piece of work.

The Diabetes Year of Care Pilot Project-Simon Eaton
Year of Care is about people with diabetes taking charge of their condition and working in partnership with healthcare professionals to plan their care. Year of Care describes all the planned care that a person with diabetes should expect to receive, usually over the course of a year. This includes support for self management in line with national standards and, where appropriate, planned specialist referrals.
This national pilot project, backed by Diabetes UK, the Department of Health and the National Diabetes Support Team, aims to find out how this will work in practice. The annual review appointment will become a care planning discussion where the person with diabetes is on equal footing with the healthcare professional. They will jointly decide on the right options for them. The plan they arrive at will form the basis of their individual Year of Care, which will have implications for commissioning. The pilot will test whether it is feasible for the system to work around individual needs in this way.
North Tyneside has been selected as a pilot site, along with Calderdale and Kirklees and Tower Hamlets. Please contact me if you would like any further information -Simon Eaton

RECENT PUBLICATIONS FROM THE NORTHEAST
Please send us your recent publication for inclusion in the next newsletter.
Dashora UK, Sibal L, Ashwell SG, Home PD. Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomised placebo-controlled trial. Diabetic Medicine 2007; 24(4):344-9.
Al-Ozairi E, Sibal L, Home PD. Counterpoint: ADOPT; good for sulfonylureas? Diabetes Care 2007; Jun;30(6):1677-80.
Advani A, Kelly DJ, Advani SL, Cox AJ, Thai K, Zhang Y, White KE, Gow RM, Marshall SM, Steer BM, Marsden PA, Gilbert RE (2007) Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions. Proc Natl Acad Sci USA 104, 14448-14453.
Raivio T, Falardeau J, Dwyer AA, Quinton R, Hayes FJ, Hughes VA, Cole LW, Pearce SHS, Lee H, Boepple P, Crowley WF, Jr, Pitteloud N. 2007 Reversal of congenital idiopathic hypogonadotropic hypogonadism. New England Journal of Medicine. 357: 863-873. 457-463. [with Editorial Comment: “Experiments of nature -a glimpse into the mysteries of the pubertal clock”, pp929-932].
Maggi M, Schulman C, Quinton R, Langham S, Uhl-Hochgräber K. 2007 The burden of testosterone deficiency in adult men: economic and quality-of-life impact. Journal of Sexual Medicine. 4: 1056-1069.
Rossor AM, Pearce SH, Adams PC. Left ventricular apical ballooning (takotsubo cardiomyopathy) in thyrotoxicosis. Thyroid. 2007; 17:181-2.
Fanciulli M, Norsworthy PJ, Petretto E, Dong R, Harper L, Kamesh L, Heward JM, Gough SC, Froguel P, Owen CJ, Pearce SHS, Teixeira L, Guillevin L, Cunningham Graham DS, Pusey CD, Cook HT, Vyse TJ, Aitman TJ. FCGR3B copy number variation is associated with susceptibility to systemic but not organ-specific autoimmunity. Nature Genetics. 2007; 39: 721-3.
Donaldson P, Veeramani S, Baragiotta A, Floreani A, Venturi C, Pearce S, Wilson V, Jones D, James O, Taylor J, Newton J, Bassendine M. Cytotoxic T-Lymphocyte-Associated Antigen-4 Single Nucleotide Polymorphisms and Haplotypes in Primary Biliary Cirrhosis. Clin Gastroenterol Hepatol. 2007; 5: 755-60.
Sutherland A, Davies J, Owen CJ, Vaikkakara S, Cheetham TD, James RA, Perros P, Cordell HJ, Donaldson PT, Quinton R, Pearce SHS. Genomic polymorphism at the interferon-induced helicase (IFIH1) locus is associated with Graves’ disease. J Clin Endocrinol Metab 2007: 92(8):3338-41.
Razvi S, Pearce SHS. Do antithyroid drugs influence outcome after radioiodine therapy for hyperthyroidism? Nat Clin Pract Endocrinol Metab 2007; 3: 628-9.


RECENT PUBLICATIONS IN DIABETES & ENDOCRINOLOGY THAT HIT THE NEWS OR THAT MAY HAVE A SIGNIFICANT IMPACT ON MANAGEMENT

Clinical update:adverse effects of antiretroviral therapy. Calmy A, et al. Lancet 2007;370:12-14. An excellent article summarising the metabolic problems associated with antiretroviral therapy. Essential reading for trainees.

Vitamin D Deficiency. Michael Holick. NEJM 2007;357:266-281. An excellent review and essential reading for trainees.

Clinical update: new treatments for hot flushes. Vered Stearns. Lancet 2007;369:2062-2064. A symptom we often come across as Endocrinologists which can be very difficult to treat. This update is well worth a read.

Polycystic Ovary Syndrome. Norman RJ, et al. Lancet 2007;370:685-697. An excellent review discussing pathophysiology, epidemiology, diagnosis and management. Well worth a read for an update.

Diagnosis and management of chronic fatigue syndrome or myalgic encephalomyelitis (or encephalopathy); Summary of NICE guidance. Baker R, Shaw EJ. BMJ 2007;335:446-448. Editorial White P, et al. BMJ 2007:411-412. Well worth a read for those of you have to deal with the common referral of “lethargy”.

Hypertriglyceridaemia. John Brunzell. NEJM 2007;357:1009-1017. An excellent practical review.

Gynecomastia. Glenn Braunstein. NEJM 2007;357:1229-1237. Mandatory reading for trainees. An excellent practical account. After reading it, I had a referral in clinic the next day. I had found this article useful.
Reversal of idiopathic hypogonadotropic hypogonadism. Raivio T, Falardeau J, Dwyer A, Quinton R, Hayes FJ, Hughes VA, Cole LW, Pearce SH, et al. N Engl J Med. 2007 Aug 30;357(9):863-73. The authors describe 15 men in whom reversal of idiopathic hypogonadotropic hypogonadism was sustained after discontinuation of hormonal therapy. Sustained reversal of idiopathic hypogonadotropic hypogonadism was defined as the presence of normal adult testosterone levels after hormonal therapy was discontinued. Ten sustained reversals were identified retrospectively. Five sustained reversal were identified prospectively among 50 men with idiopathic hypogonadotropic hypogonadism after a mean (+/-SD) duration of treatment interruption of 6+/-3 weeks. Of the 15 men who had a sustained reversal, 4 had anosmia. At initial evaluation, 6 men had absent puberty, 9 had partial puberty, and all had abnormal secretion of GnRH-induced luteinising hormone. All 15 men had received previous hormonal therapy. Among those whose hypogonadism was reversed, the mean serum level of endogenous testosterone increased from 1.9+/-1.0 nmol/l to 13.4+/-3.2 nmol/l (P<0.001),> or =90 mm Hg) were randomly assigned to receive once-daily aliskiren 150 mg (n=437), valsartan 160 mg (455), a combination of aliskiren 150 mg and valsartan 160 mg (446), or placebo (459) for 4 weeks, followed by forced titration to double the dose to the maximum recommended dose for another 4 weeks. The primary endpoint was change in mean sitting diastolic blood pressure from baseline to week 8 endpoint. Analyses were done by intention to treat. 196 (11%) patients discontinued study treatment before the end of the trial (63 in the placebo group, 53 in the aliskiren group, 43 in the valsartan group, and 37 in the aliskiren/valsartan group), mainly due to lack of therapeutic effect. At week 8 endpoint, the combination of aliskiren 300 mg and valsartan 320 mg lowered mean sitting diastolic blood pressure from baseline by 12.2 mm Hg, significantly more than either monotherapy (aliskiren 300 mg 9.0 mm Hg decrease, p<0.0001; valsartan 320 mg, 9.7 mm Hg decrease, p<0.0001), or with placebo (4.1 mm Hg decrease, p<0.0001). Rates of adverse events and laboratory abnormalities were similar in all groups. In conclusion, the combination of aliskiren and valsartan at maximum recommended doses provides significantly greater reductions in blood pressure than does monotherapy with either agent in patients with hypertension, with a tolerability profile similar to that with aliskiren and valsartan alone. This study uses a new class of antihypertensive drugs that are active oral inhibitors of rennin. The accompanying editorial provides an excellent summary (Birkenhager W, Staessen JA Lancet 2007;320:195-196).Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial. Farmer A, et al. BMJ 2007;335:132-136. This Three arm, open, parallel group randomised trial set in 48 general practices in Oxfordshire and South Yorkshire recruited 453 patients with non-insulin treated type 2 diabetes (mean age 65.7 years) for a median duration of three years and a mean HbA1c level of 7.5%. The patients were randomized into either of the following 3 treatments arms: standardised usual care with measurements of HbA1c every three months as the control group (n=152); blood glucose self monitoring with advice for patients to contact their doctor for interpretation of results, in addition to usual care (n=150); blood glucose self monitoring with additional training of patients in interpretation and application of the results to enhance motivation and maintain adherence to a healthy lifestyle (n=151). At 12 months the differences in HbA1c level between the three groups (adjusted for baseline HbA1c level) were not statistically significant (P=0.12). The difference in unadjusted mean change in HbA1c level from baseline to 12 months between the control and less intensive self monitoring groups was -0.14% (95% confidence interval -0.35% to 0.07%) and between the control and more intensive self monitoring groups was -0.17% (-0.37% to 0.03%). This trial’s evidence is not convincing of an effect of self monitoring blood glucose, with or without instruction in incorporating findings into self care, in improving glycaemic control compared with usual care in reasonably well controlled non-insulin treated patients with type 2 diabetes. This is a very emotive subject and Simon Heller’s accompanying editorial (BMJ 2007;335:105-106) provides excellent “advice”. The bottom line is that we as clinicians should discuss the value of blood monitoring in our patients and only advocate its use and continued use in patients who utilize the results to self-manage their diabetes. However, this fact is lost in primary care with Type 2 Diabetic patients on insulin being advised to test twice a week if that! Furthermore, the special group of pregnant diabetic patients often need to jump through hoops to get glucose monitoring strips. Who said type 2 diabetes is easy!Estrogen therapy and coronary-artery calcification. Manson JE, Allison MA, et al. NEJM 2007;356:2591-2602. This sub study of the Women's Health Initiative trial of conjugated equine oestrogens (0.625 mg per day) as compared with placebo in women who had undergone hysterectomy, computed tomography of the heart was performed in 1064 women aged 50 to 59 years at randomisation. Imaging was conducted at 28 of 40 centres after a mean of 7.4 years of treatment and 1.3 years after the trial was completed (8.7years after randomization). Coronary-artery calcium (or Agatston) scores were measured at a central reading centre without knowledge of randomization status. The mean coronary-artery calcium score after trial completion was lower among women receiving oestrogen (83.1) than among those receiving placebo (123.1) (P=0.02 by rank test). After adjustment for coronary risk factors, the multivariate odds ratios for coronary-artery calcium scores of more than 0, 10 or more, and 100 or more in the group receiving oestrogen as compared with placebo were 0.78 (95% confidence interval, 0.58 to 1.04), 0.74 (0.55 to 0.99), and 0.69 (0.48 to 0.98), respectively. The corresponding odds ratios among women with at least 80% adherence to the study oestrogen or placebo were 0.64 (P=0.01), 0.55 (P<0.001), and 0.46 (P=0.001). For coronary-artery calcium scores of more than 300 (vs. <10), the multivariate odds ratio was 0.58 (P=0.03) in an intention-to-treat analysis and 0.39 (P=0.004) among women with at least 80% adherence. In conclusion, among women 50 to 59 years old at enrolment, the calcified-plaque burden in the coronary arteries after trial completion was lower in women assigned to oestrogen than in those assigned to placebo. This study lends support to the timing hypothesis that oestrogen has differing effects on blood vessels in younger women than in women long after the menopause.Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled intention to treat. 196 (11%) patients discontinued study treatment before the end of the trial (63 in the placebo group, 53 in the aliskiren group, 43 in the valsartan group, and 37 in the aliskiren/valsartan group), mainly due to lack of therapeutic effect. At week 8 endpoint, the combination of aliskiren 300 mg and valsartan 320 mg lowered mean sitting diastolic blood pressure from baseline by 12.2 mm Hg, significantly more than either monotherapy (aliskiren 300 mg 9.0 mm Hg decrease, p<0.0001; valsartan 320 mg, 9.7 mm Hg decrease, p<0.0001), or with placebo (4.1 mm Hg decrease, p<0.0001). Rates of adverse events and laboratory abnormalities were similar in all groups. In conclusion, the combination of aliskiren and valsartan at maximum recommended doses provides significantly greater reductions in blood pressure than does monotherapy with either agent in patients with hypertension, with a tolerability profile similar to that with aliskiren and valsartan alone. This study uses a new class of antihypertensive drugs that are active oral inhibitors of rennin. The accompanying editorial provides an excellent summary (Birkenhager W, Staessen JA Lancet 2007;320:195-196).Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial. Farmer A, et al. BMJ 2007;335:132-136. This Three arm, open, parallel group randomised trial set in 48 general practices in Oxfordshire and South Yorkshire recruited 453 patients with non-insulin treated type 2 diabetes (mean age 65.7 years) for a median duration of three years and a mean HbA1c level of 7.5%. The patients were randomized into either of the following 3 treatments arms: standardised usual care with measurements of HbA1c every three months as the control group (n=152); blood glucose self monitoring with advice for patients to contact their doctor for interpretation of results, in addition to usual care (n=150); blood glucose self monitoring with additional training of patients in interpretation and application of the results to enhance motivation and maintain adherence to a healthy lifestyle (n=151). At 12 months the differences in HbA1c level between the three groups (adjusted for baseline HbA1c level) were not statistically significant (P=0.12). The difference in unadjusted mean change in HbA1c level from baseline to 12 months between the control and less intensive self monitoring groups was -0.14% (95% confidence interval -0.35% to 0.07%) and between the control and more intensive self monitoring groups was -0.17% (-0.37% to 0.03%). This trial’s evidence is not convincing of an effect of self monitoring blood glucose, with or without instruction in incorporating findings into self care, in improving glycaemic control compared with usual care in reasonably well controlled non-insulin treated patients with type 2 diabetes. This is a very emotive subject and Simon Heller’s accompanying editorial (BMJ 2007;335:105-106) provides excellent “advice”. The bottom line is that we as clinicians should discuss the value of blood monitoring in our patients and only advocate its use and continued use in patients who utilize the results to self-manage their diabetes. However, this fact is lost in primary care with Type 2 Diabetic patients on insulin being advised to test twice a week if that! Furthermore, the special group of pregnant diabetic patients often need to jump through hoops to get glucose monitoring strips. Who said type 2 diabetes is easy!Estrogen therapy and coronary-artery calcification. Manson JE, Allison MA, et al. NEJM 2007;356:2591-2602. This sub study of the Women's Health Initiative trial of conjugated equine oestrogens (0.625 mg per day) as compared with placebo in women who had undergone hysterectomy, computed tomography of the heart was performed in 1064 women aged 50 to 59 years at randomisation. Imaging was conducted at 28 of 40 centres after a mean of 7.4 years of treatment and 1.3 years after the trial was completed (8.7years after randomization). Coronary-artery calcium (or Agatston) scores were measured at a central reading centre without knowledge of randomization status. The mean coronary-artery calcium score after trial completion was lower among women receiving oestrogen (83.1) than among those receiving placebo (123.1) (P=0.02 by rank test). After adjustment for coronary risk factors, the multivariate odds ratios for coronary-artery calcium scores of more than 0, 10 or more, and 100 or more in the group receiving oestrogen as compared with placebo were 0.78 (95% confidence interval, 0.58 to 1.04), 0.74 (0.55 to 0.99), and 0.69 (0.48 to 0.98), respectively. The corresponding odds ratios among women with at least 80% adherence to the study oestrogen or placebo were 0.64 (P=0.01), 0.55 (P<0.001), and 0.46 (P=0.001). For coronary-artery calcium scores of more than 300 (vs. <10), the multivariate odds ratio was 0.58 (P=0.03) in an intention-to-treat analysis and 0.39 (P=0.004) among women with at least 80% adherence. In conclusion, among women 50 to 59 years old at enrolment, the calcified-plaque burden in the coronary arteries after trial completion was lower in women assigned to oestrogen than in those assigned to placebo. This study lends support to the timing hypothesis that oestrogen has differing effects on blood vessels in younger women than in women long after the menopause.
Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled